Pfizer's OcuHist: Antihistamine eyedrops containing pheniramine maleate (.3%) and decongestant naphazoline hydrochloride (.025%) are launching April 1. Pfizer is marketing the product under a licensing arrangement with Akorn, which obtained Rx-to-OTC switch approval for OcuHist on Jan. 31 ("The Tan Sheet" Feb. 12, p. 5). The launch will be supported by network TV ads, consumer couponing and print ads and direct mail to eye-care specialists. Pfizer also sells Visine eye drops...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
